These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 25519162

  • 1. Evaluation of High-Dose Daptomycin Versus Vancomycin Alone or Combined with Clarithromycin or Rifampin Against Staphylococcus aureus and S. epidermidis in a Novel In Vitro PK/PD Model of Bacterial Biofilm.
    Hall Snyder AD, Vidaillac C, Rose W, McRoberts JP, Rybak MJ.
    Infect Dis Ther; 2014 Dec 18; 4(1):51-65. PubMed ID: 25519162
    [Abstract] [Full Text] [Related]

  • 2. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
    Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ.
    Antimicrob Agents Chemother; 2010 Oct 18; 54(10):4329-34. PubMed ID: 20696880
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Barber KE, Smith JR, Ireland CE, Boles BR, Rose WE, Rybak MJ.
    Antimicrob Agents Chemother; 2015 Aug 18; 59(8):4497-503. PubMed ID: 25987623
    [Abstract] [Full Text] [Related]

  • 4. Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms.
    Kunz Coyne AJ, Stamper K, Bleick C, Kebriaei R, Lehman SM, Rybak MJ.
    Microbiol Spectr; 2024 Apr 02; 12(4):e0321223. PubMed ID: 38411110
    [Abstract] [Full Text] [Related]

  • 5. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model.
    Jahanbakhsh S, Singh NB, Yim J, Kebriaei R, Smith JR, Lev K, Tran TT, Rose WE, Arias CA, Rybak MJ.
    Antimicrob Agents Chemother; 2020 Apr 21; 64(5):. PubMed ID: 32094136
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Biofilm Model.
    Jahanbakhsh S, Singh NB, Yim J, Rose WE, Rybak MJ.
    Antimicrob Agents Chemother; 2018 Aug 21; 62(8):. PubMed ID: 29784849
    [Abstract] [Full Text] [Related]

  • 7. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A, Cafiso V, Campanile F, Parisi G, Mariani B, Petrosillo N, Stefani S.
    Eur J Clin Microbiol Infect Dis; 2016 Apr 21; 35(4):625-31. PubMed ID: 26815434
    [Abstract] [Full Text] [Related]

  • 8. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR, Barber KE, Hallesy J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2015 Sep 21; 59(9):5529-34. PubMed ID: 26124162
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of Omadacycline Alone and in Combination with Rifampin against Staphylococcus aureus and Staphylococcus epidermidis in an In Vitro Pharmacokinetic/Pharmacodynamic Biofilm Model.
    Morrisette T, Stamper KC, Lev KL, Kebriaei R, Holger DJ, Abdul-Mutakabbir JC, Kunz Coyne AJ, Rybak MJ.
    Antimicrob Agents Chemother; 2023 Jun 15; 67(6):e0131722. PubMed ID: 37222591
    [Abstract] [Full Text] [Related]

  • 10. Comparative efficacy of dalbavancin alone and with rifampicin against in vitro biofilms in a pharmacodynamic model with methicillin-resistant Staphylococcus aureus.
    El Haj C, Benavent E, Sierra Y, Soldevila L, Rigo-Bonnin R, Torrejón B, Gomez-Junyent J, Rosselló I, Murillo O.
    Int J Antimicrob Agents; 2022 Oct 15; 60(4):106664. PubMed ID: 36002115
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of linezolid or trimethoprim/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm.
    El Haj C, Murillo O, Ribera A, Lloberas N, Gómez-Junyent J, Tubau F, Fontova P, Cabellos C, Ariza J.
    Int J Antimicrob Agents; 2018 Jun 15; 51(6):854-861. PubMed ID: 29374577
    [Abstract] [Full Text] [Related]

  • 12. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
    Steed ME, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2010 Dec 15; 54(12):5187-92. PubMed ID: 20921318
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN, Rybak MJ.
    J Antimicrob Chemother; 2009 Jan 15; 63(1):155-60. PubMed ID: 18984644
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ, Barber KE, Ireland CE, Rybak MJ.
    Antimicrob Agents Chemother; 2014 Jun 15; 58(6):3177-81. PubMed ID: 24663016
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed M, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2011 Jul 15; 55(7):3522-6. PubMed ID: 21576449
    [Abstract] [Full Text] [Related]

  • 16. Pre-clinical Impact of the Synergistic Mechanism of Daptomycin and Ceftaroline on Patients with Methicillin-resistant Staphylococcus aureus Bacteremia Infections.
    Eliazar J, Johnson T, Chbib C.
    Curr Rev Clin Exp Pharmacol; 2021 Jul 15; 16(4):296-299. PubMed ID: 33423652
    [Abstract] [Full Text] [Related]

  • 17. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.
    LaPlante KL, Woodmansee S.
    Antimicrob Agents Chemother; 2009 Sep 15; 53(9):3880-6. PubMed ID: 19564363
    [Abstract] [Full Text] [Related]

  • 18. Emergence of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Clinical Isolates Among Daptomycin-Naive Patients in Korea.
    Nam EY, Yang SJ, Kim ES, Cho JE, Park KH, Jung SI, Yoon N, Kim DM, Lee CS, Jang HC, Park Y, Lee KS, Kwak YG, Lee JH, Park SY, Hwang JH, Kim M, Song KH, Kim HB.
    Microb Drug Resist; 2018 Jun 15; 24(5):534-541. PubMed ID: 29863982
    [Abstract] [Full Text] [Related]

  • 19. Daptomycin combinations as alternative therapies in experimental foreign-body infection caused by meticillin-susceptible Staphylococcus aureus.
    El Haj C, Murillo O, Ribera A, Vivas M, Garcia-Somoza D, Tubau F, Cabellos C, Cabo J, Ariza J.
    Int J Antimicrob Agents; 2015 Aug 15; 46(2):189-95. PubMed ID: 26051988
    [Abstract] [Full Text] [Related]

  • 20. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL.
    Antimicrob Agents Chemother; 2014 Aug 15; 58(2):672-7. PubMed ID: 24217694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.